Introduction {#S0001}
============

Several studies have reported an association between over-loading due to obesity and the development of knee osteoarthritis (KOA).[@CIT0001]--[@CIT0004] However, based on the epidemiological correlation between hand OA and overweight or obesity, systemic factors identified in the association with KOA may also be involved in general OA pathology.[@CIT0005]--[@CIT0008] Some epidemiological studies have also suggested an association of diabetes mellitus (DM) and hyperglycemia with OA.[@CIT0009]--[@CIT0013] However, the mechanism underlying such an association is not fully understood.

Toll-like receptors (TLRs) are transmembrane proteins with roles in DM pathology. Among the TLR subtypes, TLR2 and TLR4 play an important role in DM pathology in both experimental and clinical conditions.[@CIT0014]--[@CIT0016] TLR4-mediated chronic inflammation is also associated with DM complications such as diabetic neuropathy, diabetic retinopathy, and diabetic nephropathy.[@CIT0017] Interestingly, TLR4 is also expressed in joint tissues and contributes to OA pathology via inflammation and inflammation-induced catabolism.[@CIT0018],[@CIT0019] TLR4 deficiency decreases disease severity, as evidenced by lower bone erosion, cartilage damage, and synovial cellular influx.[@CIT0020] However, whether TLR4 levels are elevated in KOA patients with DM remains to be determined.

TLR4 signaling contributes to catabolic responses and results in elevated production of matrix metalloproteinase (MMP). Among the MMP subtypes, *MMP13* expression is most localized to connective tissue,[@CIT0021] where it degrades type II, IV and IX collagen in articular cartilage,[@CIT0022] and is a key enzyme targeting cartilage for degradation. TLR4 is linked to *MMP13* expression.[@CIT0022],[@CIT0023] TLR4 deficiency reduces *MMP13* expression in mice.[@CIT0023] Interestingly, a recent study showed that glucose treatment of zebrafish induced diabetic conditions and increased *MMP13* expression.[@CIT0024] We therefore hypothesized that MMP13 may be elevated in KOA patients under diabetic conditions.

Here, we compared *TLR* and *MMP* expression in synovial tissue (SYN) between KOA patients with and without high haemoglobin A1c concentrations.

Materials and methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

Power analysis using an alpha of 0.05, power of 0.80, and N2 (number of patients with HbA1c ≥6.5)/N1 (number of patients with HbA1c \<6.5) ratio of 0.155 was conducted in G\*POWER3 to determine the optimal sample size. Power analysis revealed that 23 patients with HbA1c ≥6.5 and 148 patients with HbA1c \<6.5 were needed to detect a difference in TLR4 between HbA1c ≥6.5 and HbA1c \<6.5 groups.

We examined SYN from patients (38 men and 133 women) with KOA diagnosed by radiography who underwent total knee arthroplasty at our institution. KOA patients with a cancer diagnosis, trauma, rheumatoid arthritis or other collagen diseases were excluded from this study. SYN samples were harvested from the operated knee during the operation. A piece of each of the 171 SYN specimens was snap frozen in liquid nitrogen at −80 °C prior to RNA extraction. Eight SYN specimens were used for cell culture.

This study protocol received approval by the Ethics Review Board of Kitasato University (reference number: KMEO B13-113). Written informed consent was obtained from all participants regarding participation in the study and the removal and use of their SYN one day prior to surgery. This study was conducted in accordance with the Declaration of Helsinki.

Quantitative polymerase chain reaction (qPCR) analysis {#S0002-S2002}
------------------------------------------------------

To evaluate the effect of the diabetic state on *TLR* and *MMP* expression, OA patients were grouped based on their HbA1c concentration (HbA1c ≥6.5 and HbA1c \<6.5).[@CIT0025] Patients' clinical characteristics are summarized in [Table 1](#T0001){ref-type="table"} by group. Methods for total RNA extraction, cDNA synthesis and qPCR using SYBR Green are described elsewhere.[@CIT0026] The following PCR primers were used for qPCR: *TLR2*-sense 5ʹ-CCT GTG TGA CTC TCC ATC CC-3ʹ, *TLR2*-antisense 5ʹ-GAC ATT CCG ACA CCG AGA GG-3 (product size: 71 bp); *TLR4*-sense 5ʹ-CGA CAA CCT CCC CTT CTC AAC-3ʹ, *TLR4*-antisense 5ʹ-AGA GGT GGC TTA GGC TCT GAT-3 (product size: 167 bp); *MMP2*-sense 5ʹ-GTG AAG TAT GGG AAC GCC GA-3ʹ, *MMP2*-antisense 5ʹ-AGA AGC CGT ACT TGC CAT CC-3 (product size: 154 bp); *MMP3*-sense 5ʹ-GTG GAG TTC CTG ACG TTG GT-3ʹ, *MMP3*-antisense 5ʹ-TGG AGT CAC CTC TTC CCA GA-3 (product size: 164 bp); *MMP9*-sense 5ʹ-TTT GAG TCC GGT GGA CGA TG-3ʹ, *MMP9*-antisense 5ʹ-GCT CCT CAA AGA CCG AGT CC-3 (product size: 197 bp); *MMP13*-sense 5ʹ-TGA CTG AGA GGC TCC GAG AA-3ʹ, *MMP13*-antisense 5ʹ-CAT CAG GAA CCC CGC ATC TT-3 (product size: 111 bp); *GAPDH*-sense 5ʹ-TGT TGC CAT CAA TGA CCC CTT-3ʹ and *GAPDH*-antisense 5ʹ-CTC CAC GAC GTA CTC AGC G-3ʹ (product size: 202 bp). *TLR* and *MMP* mRNA expression levels were normalized to *GAPDH* levels using the delta-delta Ct method. We compared the expression of *TLR2, TLR4, MMP2, MMP3, MMP9* and *MMP13* in the SYN between the two HbA1c groups. Additionally, we grouped the patients based on the World Health Organization Body Mass Index (BMI) classification ([Table 2](#T0002){ref-type="table"}) (normal, overweight, obese) and compared *TLR2, TLR4, MMP2, MMP3, MMP9* and *MMP13* expression among these groups. Relative expression was calculated using the mean of all control samples (samples from SYN from the HbA1c \<6.5 group or α-MEM-treated SYN cells in vitro). To investigate potential gender effects, female and male KOA patients were grouped based on their HbA1c level and BMI and *TLR4* and *MMP13* levels were analyzed.Table 1Patients' clinical characteristics by HbA1c groupHbA1c \<6.5 (n=148)HbA1c ≥6.5 (n=23)*P*Age (years)73.9±0.774.0±1.70.944Male/Female, n34/1144/190.787KL (2/3/4), n3/51/940/5/180.451BMI (kg/m^2^)25.8±0.330.0±0.8\*\<0.001[^1][^2] Table 2Patients' clinical characteristics by body mass index groupNormal (n=69)Overweight (n=72)Obese (n=30)*P*Age (years)76.0±0.973.9±0.869.3±1.6^a,b^\<0.001Male/Female, n11/5823/494/260.037KL (2/3/4), n2/19/481/28/430/9/210.591HbA1c5.8±0.06.0±0.16.3±0.1^a,b^\<0.001[^3][^4]

Cell culture {#S0002-S2003}
------------

SYN cells derived from 8 patients were used to examine the effect of the TLR4 agonist, LPS, on *MMP13* mRNA expression and MMP13 protein production. Synovial cells were obtained following collagenase digestion of SYN as reported previously.[@CIT0027] Isolated synovial cells were cultured in 6-well plates in α-minimal essential media (α-MEM) with 10% fetal bovine serum. One week later, the cell population of cultured SYN cells was determined using flow cytometric analysis as reported previously.[@CIT0027] The cultured SYN cells were incubated with FITC-conjugated anti-CD45 (Biolegend, CA, USA) and allophycocyanin (APC)-conjugated anti-CD90 (Biolegend) antibodies for 45 min at 4 °C. After washing twice in PBS, 50,000 total events were acquired using FACSVerseTM (BD Biosciences, San Jose, CA, USA), and the data were analyzed using Flow Jo 10.0 (Tree Star, Ashland, OR). SYN cells were exposed to 1000 μL of 0 (α-MEM), 100 or 1000 ng/mL LPS (Sigma, St. Louis, MO, USA) for 24 h. Subsequently, *MMP13* mRNA expression was examined using qPCR with the primers described above. MMP13 protein concentration in the cell supernatant was analyzed using a commercial ELISA kit (Human Pro-MMP-13 Quantikine ELISA Kit, R&D Systems, Inc., Minneapolis, MN, USA).

Statistical analysis {#S0002-S2004}
--------------------

The SPSS 25.0 statistical package was used for statistical analysis. Continuous variables were analyzed using the Mann-Whitney U test and Tukey multiple comparisons test, and categorical variables were analyzed using Fisher's exact test. Statistical significance was defined by *P*\<0.05.

Results {#S0003}
=======

Clinical characteristics of patients with HbA1c ≥6.5 and HbA1c \<6.5 {#S0003-S2001}
--------------------------------------------------------------------

BMI among KOA patients with HbA1c ≥6.5 was significantly higher than that among KOA patients with HbA1c \<6.5 ([Table 1](#T0001){ref-type="table"}). Age, male/female ratio and Kellgren/Lawrence grade 2/3/4 ratio were similar between the groups ([Table 1](#T0001){ref-type="table"}).

Expression of TLRs and MMPs among patients with HbA1c ≥6.5 and HbA1c \<6.5 {#S0003-S2002}
--------------------------------------------------------------------------

To determine whether TLR and MMP expression levels are increased in diabetic KOA patients, we examined TLRs and MMPs in the SYN of KOA patients with HbA1c ≥6.5 and HbA1c \<6.5. *TLR2* expression was similar between patients with HbA1c ≥6.5 and HbA1c \<6.5 (*P*=0.078; [Figure 1A](#F0001){ref-type="fig"}), while *TLR4* expression in the HbA1c ≥6.5 group was significantly higher than that in the HbA1c \<6.5 group (*P*=0.040; [Figure 1B](#F0001){ref-type="fig"}). There were no differences in *MMP2, MMP3*, or *MMP9* expression between the groups (*MMP2, P*=0.626; *MMP3, P*=0.876; *MMP9, P*=0.912; [Figure 1C](#F0001){ref-type="fig"}--[E](#F0001){ref-type="fig"}). *MMP13* expression in the HbA1c ≥6.5 group was significantly higher than that in the HbA1c \<6.5 group (*P*\<0.001; [Figure 1F](#F0001){ref-type="fig"}).Figure 1Effect of HbA1c concentration on *TLR* and *MMP* expression in the synovium. *TLR2* (**A**), *TLR4* (**B**), *MMP2* (**C**), *MMP3* (**D**), *MMP9* (**E**) and *MMP13* (**F**) expression in patients with HbA1c ≥6.5 and HbA1c \<6.5. \**P*\<0.05 compared with HbA1c \<6.5 group.

Effect of obesity on expression of TLRs and MMPs {#S0003-S2003}
------------------------------------------------

Patients in the HbA1c ≥6.5 group had higher BMI than those in the HbA1c \<6.5 group. We therefore investigated the effect of obesity on the expression of TLRs and MMPs. Patients in the obese group were significantly younger than those in the normal and overweight groups ([Table 2](#T0002){ref-type="table"}). HbA1c levels in the obese group were significantly higher than those in the normal and overweight groups ([Table 2](#T0002){ref-type="table"}). The Kellgren/Lawrence grade 2/3/4 ratio was similar among the groups ([Table 2](#T0002){ref-type="table"}). Expression levels of *TLR2, TLR4, MMP2, MMP3, MMP9*, and *MMP13* were also similar among the normal, overweight, and obese groups (*TLR2, P*=0.821; *TLR4, P*=0.075; *MMP2, P*=0.294; *MMP3, P*=0.636; *MMP9, P*=0.659; *MMP13, P*=0.853; [Figure 2](#F0002){ref-type="fig"}).Figure 2Effect of obesity on *TLR* and *MMP* expression in the synovium. *TLR2* (**A**), *TLR4* (**B**), *MMP2* (**C**), *MMP3* (**D**), *MMP9* (**E**) and *MMP13* (**F**) expression in normal, overweight, and obese groups.

Gender differences in expression of TLR4 and MMP13 {#S0003-S2004}
--------------------------------------------------

Previous studies have suggested that there may be gender differences in pathological conditions in obese and diabetes patients.[@CIT0028]--[@CIT0032] Therefore, we analyzed *TLR4* and *MMP13* expression between HbA1c ≥6.5 and HbA1c \<6.5 and among normal, overweight, and obese groups separately in male and female patients. Female patients but not male patients had higher BMI in the HbA1c ≥6.5 group than in the HbA1c \<6.5 group ([Table 3](#T0003){ref-type="table"}). Among male OA patients, there was no difference in *TLR4* or *MMP13* between the HbA1c ≥6.5 and HbA1c \<6.5 group (*P*=0.216 and *P*=0.341, respectively; [Figure 3A](#F0003){ref-type="fig"} and [B](#F0003){ref-type="fig"}). *TLR4* and *MMP13* expression in female KOA patients with HbA1c ≥6.5 was significantly higher than that in female KOA patients with HbA1c \<6.5 (*P*=0.021 and *P*\<0.001, respectively; [Figure 3C](#F0003){ref-type="fig"} and [D](#F0003){ref-type="fig"}). Both male and female patients in the obese group were significantly younger than those in the normal group ([Table 4](#T0004){ref-type="table"}). HbA1c levels in female patients but not male patients were significantly higher in the obese group than in the normal and overweight groups ([Table 4](#T0004){ref-type="table"}). There were no differences in *TLR4* or *MMP13* among the normal, overweight, and obese groups in male (*TLR4, P*=0.888; *MMP13, P*=0.320; [Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}) or female (*TLR4, P*=0.096, *MMP13, P*=0.812; [Figure 4C](#F0004){ref-type="fig"} and [D](#F0004){ref-type="fig"}) KOA patients.Table 3Patients' clinical characteristics by HbA1c group and genderGenderHbA1c \<6.5 (male, n=34 female, n=114)HbA1c ≥6.5 (male, n=4; female, n=19)*P*Age (years)Male73.4±1.870.0±2.5*P*=0.535Female74.1±0.774.9±1.5*P*=0.636KL (2/3/4), nMale0/2/21/13/20*P*=1.000Female2/38/740/3/16*P*=0.296BMIMale26.6±3.228.3±2.6*P*=0.309Female25.5±0.430.4±1.0\**P*\<0.001[^5][^6] Table 4Patients' clinical characteristics by body mass index group and genderGenderNormal male, n=10 female, n=58Overweight male, n=24 female, n=49Obese male, n=4 female, n=26*P*Age (years)Male74.2±2.974.9±1.759.0±7.0^a,b^*P*=0.011Female76.7±0.973.0±1.3^a^70.8±1.3^a,b^*P*\<0.001KL (2/3/4), nMale0/2/81/12/110/1/3*P*=0.352Female2/16/400/17/320/8/18*P*=0.758HbA1c ≥6.5Male5.8±0.15.9±0.16.0±0.3*P*=0.820Female5.8±0.06.0±0.16.3±0.1^a,b^*P*\<0.001[^7] Figure 3Effect of HbA1c on *TLR4* and *MMP13* expression in the synovium of male and female patients. (**A-B**). *TLR4* (**A**) and *MMP13* (**B**) expression in male patients with HbA1c ≥6.5 and HbA1c \<6.5. C-D. *TLR4* (**C**) and *MMP13* (**D**) expression in female patients with HbA1c ≥6.5 and HbA1c \<6.5. ^\*^*P*\<0.05 compared with gender-matched HbA1c\<6.5 group.Figure 4Effect of obesity on *TLR* and *MMP* expression in the synovium of male and female patients. (**A-B**). *TLR4* (**A**) and *MMP13* (**B**) expression in male patients in the normal, overweight, and obese groups. C-D. *TLR4* (**C**) and *MMP13* (**D**) expression in female patients in the normal, overweight, and obese groups.

Effect of TLR4 ligand, LPS, on MMP13 expression and MMP13 production {#S0003-S2005}
--------------------------------------------------------------------

Flow cytometric analysis showed that almost all cells (94.5±0.9%) among cultured SYN cells were CD45- CD90+ (synovial fibroblasts) ([Figure 5A](#F0005){ref-type="fig"}). *TLR4* and *MMP13* expression levels were elevated in the synovium of OA patients with high HbA1c concentrations. We therefore investigated whether a TLR4 agonist regulates MMP13 in synovial cells. Synovial cells stimulated with 100 or 1000 ng/mL LPS exhibited significant increases in *MMP13* mRNA expression compared to vehicle-treated cells (*P*=0.006 and *P*=0.007, respectively; [Figure 5B](#F0005){ref-type="fig"}). *MMP13* protein levels in the supernatant of synovial cells treated with 100 or 1000 ng/mL LPS were also significantly higher than those of cells treated with vehicle (*P*=0.021 and *P*=0.022, respectively; [Figure 5C](#F0005){ref-type="fig"}).Figure 5Effect of the TLR4 agonist lipopolysaccharide on *MMP13* expression and MMP13 production. (**A**). Flow cytometric analysis of cultured synovial tissue-derived cells. X-axis indicates CD45, y-axis indicates CD90. (**B-C**). Effect of the TLR4 agonist lipopolysaccharide on *MMP13* expression and MMP13 production. Relative *MMP13* expression (**B**) and MMP13 protein concentration in the culture supernatant (**C**) of synovial cells treated with or without lipopolysaccharide were examined by quantitative PCR and enzyme-linked immunosorbent assay, respectively. Data indicate mean ± standard error (n=8). \**P*\<0.05.

Discussion {#S0004}
==========

Studies have shown that *TLR2* and *TLR4* expression are raised in traditional target tissues of insulin resistance such as adipose tissue and skeletal muscle in DM patients.[@CIT0033],[@CIT0034] Consistent with these reports, we observed higher *TLR4* expression in the SYN of KOA patients with high HbA1c concentrations. TLR4 is associated with inflammatory and catabolic responses, and is up-regulated in inflamed SYN[@CIT0035] and osteoarthritic lesions in OA patients.[@CIT0036] Elevated *TLR4* expression in the SYN of KOA patients with high HbA1c concentrations may therefore be associated with OA pathology.

Clinical studies have reported elevated *MMP13* expression in patients with articular cartilage destruction,[@CIT0037],[@CIT0038] indicating that raised MMP13 levels may contribute to cartilage degradation. A previous study showed that transgenic mice overexpressing *Mmp13* exhibit OA phenotype, including cartilage degradation. TLR4 signaling is associated with catabolic response via MMP13.[@CIT0039] TLR4 ligands stimulate MMP13 in human chondrocytes[@CIT0040],[@CIT0041] and synovial fibroblasts.[@CIT0042] Here, *MMP13* expression was increased in the SYN of KOA patients with high HbA1c concentrations. In addition, the TLR4 agonist, LPS, stimulated *MMP13* expression and MMP13 production. Several endogenous TLR4 ligands that may exacerbate diabetic conditions have been reported, including advanced glycation end products,[@CIT0041] macroglobulin[@CIT0043] and amyloid-β.[@CIT0044] However, it is unclear which endogenous ligands contribute to the elevation of *MMP13* in KOA patients with high HbA1c concentrations. Nevertheless, elevation of *TLR4* and *MMP13* expression in the SYN of KOA patients with high HbA1c concentrations may explain some of the epidemiological findings showing that DM is associated with OA. Previous epidemiological studies have reported that DM patients have high prevalence of overweight/obesity.[@CIT0045]--[@CIT0047] Fatani et al reported that 41% of a DM patient population was obese.[@CIT0046] Hedley et al reported that 70% of DM patients were obese.[@CIT0047] In our study, patients with HbA1c ≥6.5 had higher BMI than those with HbA1c \<6.5, and 56% of OA patients with HbA1c ≥6.5 were obese. However, *TLR4* and *MMP13* expression were comparable among normal, overweight, and obese patients. Therefore, our results suggest that higher *TLR4* and *MMP13* expression may be reflective of diabetic conditions but not obesity.

Several studies have reported gender differences in type 2 DM[@CIT0028],[@CIT0032] and obese patients.[@CIT0029]--[@CIT0031] For example, the effect of type 2 DM on the risk of coronary heart disease is greater in females than males.[@CIT0028] Fat distribution with menopause is the main contributor to obesity in females.[@CIT0030],[@CIT0031] In our study, there were no significant differences in *TLR4* or *MMP13* expression among the normal, overweight, and obese groups in either males or females. In contrast, *TLR4* and *MMP13* expression in female KOA patients with HbA1c ≥6.5 was significantly higher than that in female KOA patients with HbA1c \<6.5. No such difference was observed between male KOA patients with HbA1c ≥6.5 and HbA1c \<6.5. Our results may indicate gender differences in KOA patients with diabetes. However, our study lacked sufficient numbers of male patients for statistical analysis. Further investigations are needed to reveal the potential gender differences in KOA pathology with diabetes.

Several limitations of the present study warrant mention. First, the present study lacked oral glucose tolerance test (OGTT) data. Further characterization with OGTT data may more accurately reflect *TLR4* and *MMP13* expression in diabetic conditions. Second, the inclusion of a non-KOA population is needed to confirm whether *TLR4* and *MMP13* expression are increased in diabetic individuals and if this directly contributes to KOA progression. Measurement of MMP levels in the serum of diabetic patients with and without OA and non-diabetic controls with and without OA is needed to support our conclusion. Third, elucidation of the mechanism by which *TLR4* and *MMP13* contributes to KOA pathology is needed. Fourth, we assessed the mRNA expression of TLRs and MMPs in SYN. Further investigation, such as a protein profiling study, is needed to tie the gene expression profile results together. Fifth, a positive control using a human synovial fibroblast or chondrocyte cell line was lacking in the in vitro study. Finally, whether there is also an increase in *MMP/TLR* expression in cartilage remains to be determined.

In summary, *TLR4* and *MMP13* were elevated in the synovium of osteoarthritis patients with high HbA1c concentrations. Our results may provide insights into the pathology of KOA patients with DM.
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[^1]: **Notes:** Data represent mean ± standard error or n. \**P*\<0.05 compared with HbA1c \<6.5 group.

[^2]: **Abbreviations:** KL, Kellgren/Lawrence grade; BMI, body mass index.

[^3]: **Notes:** Data represent mean ± standard error or n. ^a^P\<0.05 compared with normal group. ^b^P\<0.05 compared with overweight group.

[^4]: **Abbreviations:** KL, Kellgren/Lawrence grade; BMI, body mass index.

[^5]: **Notes:** Data represent mean ± standard error or n. \**P*\<0.05 compared with gender-matched HbA1c \<6.5 group.

[^6]: **Abbreviations:** KL, Kellgren/Lawrence grade; BMI, body mass index.

[^7]: **Notes:** ^a^P\<0.05 compared with gender-matched normal group. ^b^P\<0.05 compared with gender-matched overweight group.
